Author(s): Huttin C, Liebman M
Abstract Share this page
Abstract This paper discusses the application of an adaptive technology platform to evaluate clinical pathways, clinical strategies and their application to early genetic testing in Europe. It results from a collaboration between Professor Christine Huttin, who created a technology startup called endepusresearchinc (www.endepusresearchinc-com) in Cambridge U.S.A. and Dr. Michael Liebman, Managing Director of Strategic Medicine, Inc.(www.strategicmedicine.com) positioned in the translational medicine space with technologies to model disease processes and experience in early genetic testing for breast cancer. Diagnostics was identified as a potential area for application of economic and business models using ENDEPUSresearchinc statistical methods combining implicit and explicit financial information for prospective payment systems in various types of health care financing systems. The new economics resulting from such platforms challenges the constrained environment for public, private laboratories and partnerships, the restrictions imposed by governmental agencies, alliances between stakeholders such as the medical profession and laboratories: such early technologies are clearly identified as a key benefit to the system over time but a major challenge for short term returns.
This article was published in Technol Health Care
and referenced in Journal of Antivirals & Antiretrovirals